Cencora, Inc.
NYSE:CORMedical - Distribution
-$5.65 today
- Market cap
- $66.47B
- Beta
- 0.59
- P/E (TTM)
- 20.7
- EPS (TTM)
- $13.10
- Dividend yield
- 0.87%
Volume 1.20M
Average 1.78M
COR EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Cencora, Inc.NYSE: COR
EBITDA · Q3 FY2026 · quarter ended Jun 2026
EBITDA grows, but more slowly than its trailing trend
Q3 FY2026 EBITDA of $1.42B rose 12.0% year over year, behind the +28.2% change in trailing-twelve-month EBITDA. Sequentially, it fell 43.2% from the prior quarter. Over 3 fiscal years it compounded at +6.2% a year.
Context
- EBITDA amounted to 1.2% of revenue in FY2025, unchanged from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 9 analysts of $6.12B (+63.4%) for the fiscal year ending Sep 2026, a step up from the +11.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $1.42B-43.2% QoQ
- Last fiscal yearSep 2025
- $3.75B+11.1% YoY
- LTMJun 2026
- $5.15B+28.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +12.0% | +752.0% | +740.0 pp |
| 1 year | +11.1% | +63.4% | +52.3 pp |
| 3-year CAGR | +6.2% | +22.5% | +16.3 pp |
| 5-year CAGR | +17.3% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 3.75B USD
- Year-over-year change
- +11.1%
- 4-year CAGR
- +6.4%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 3.75B | +11.1% |
| FY2024 | 2024-09-30 | 3.37B | -1.3% |
| FY2023 | 2023-09-30 | 3.42B | +9.4% |
| FY2022 | 2022-09-30 | 3.12B | +7.0% |
| FY2021 | 2021-09-30 | 2.92B | — |
EBITDA vs competitors
How COR compares with its peers on the latest reported figures
- COR's LTM Jun 2026 EBITDA of $5.15B is the 2nd highest of the 5 companies compared; the peer median is $2.31B.
- Its year-over-year change of +28.2% is the 3rd highest of 5, against a peer median of +25.5%.
- EBITDA amounts to 1.5% of revenue for COR, versus a peer median of 4.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $7.34B | +41.5% | +9.4% | 1.8% | |
| LTM Jun 2026 | $5.15B | +28.2% | +6.2% | 1.5% | |
| LTM Sep 2026 | $3.58B | +9.6% | +34.2% | 1.4% | |
| LTM Jun 2026 | $1.05B | +8.7% | +1.0% | 7.7% | |
| LTM Mar 2026 | $344.06M | +949.6% | -0.3% | 12.7% | |
| Peer median (excluding COR) | $2.31B | +25.5% | +5.2% | 4.7% | |
Competitors are the stored peer set for COR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Revenue | 213.99B | 238.59B | 262.17B | 293.96B | 321.33B |
| Cost of Revenue | 207.72B | 230.99B | 254.42B | 285.26B | 311.19B |
| Gross Profit | 6.27B | 7.6B | 7.76B | 8.7B | 10.14B |
| Gross Margin | 2.9% | 3.2% | 3.0% | 3.0% | 3.2% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 3.59B | 4.85B | 5.31B | 5.66B | 6.49B |
| Operating Expenses | 3.59B | 4.85B | 5.31B | 5.66B | 6.49B |
| Depreciation & Amortization | 514.79M | 709.84M | 980.85M | 1.12B | 1.07B |
| EBITDA | 2.92B | 3.12B | 3.42B | 3.37B | 3.75B |
| EBITDA Margin | 1.4% | 1.3% | 1.3% | 1.1% | 1.2% |
| Operating Income | 2.68B | 2.75B | 2.45B | 3.04B | 3.65B |
| Operating Margin | 1.3% | 1.2% | 0.9% | 1.0% | 1.1% |
| Interest Income | 8.47M | 21.31M | 46.72M | 91.69M | 128.21M |
| Interest Expense | 182.54M | 231.98M | 275.65M | 248.68M | 419.75M |
| Other Income / Expenses | (453.15M) | (568.62M) | (285.68M) | (1.04B) | (1.39B) |
| Income Before Tax | 2.22B | 2.18B | 2.16B | 2B | 2.26B |
| Pre-Tax Margin | 1.0% | 0.9% | 0.8% | 0.7% | 0.7% |
| Income Tax Expense | 677.25M | 516.52M | 428.26M | 484.7M | 690.52M |
| Net Income | 1.54B | 1.7B | 1.75B | 1.51B | 1.55B |
| Net Margin | 0.7% | 0.7% | 0.7% | 0.5% | 0.5% |
| EPS (Basic) | 7.48 | 8.15 | 8.62 | 7.60 | 8.02 |
| EPS (Diluted) | 7.39 | 8.04 | 8.53 | 7.53 | 7.96 |
| Weighted Avg Shares | 205.92M | 208.47M | 204.59M | 198.5M | 193.82M |
| Weighted Avg Shares (Diluted) | 208.47M | 211.21M | 204.59M | 200.28M | 195.21M |
Cencora, Inc.
NYSE:COR
Intrinsic Alpha fair value
Locked
Current Price
$348.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.